Myrio Tx
Ben Kiefel is an accomplished leader in the biotechnology field, currently serving as CEO of Psaio Tx since March 2024 and as Co-Founder of Hula Therapeutics since May 2021. Additionally, Ben Kiefel has been the COO of Myrio Tx since January 2010, where the focus is on finalizing the development of the innovative protein display platform, ReD (Retained Display). Prior experience includes roles as COO and Research Officer at Alchemy Biosciences from September 2006 to January 2010. Ben Kiefel holds a Doctor of Philosophy (PhD) in Evolutionary Biology from Deakin University, earned from 2001 to 2006.
This person is not in any teams
Myrio Tx
Cancer will have no place to hide... Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies. Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.